Dusseldorf - Delayed Quote EUR

Savara Inc (YB4P.DU)

2.0000

+0.1300

+(6.95%)

At close: May 30 at 7:30:41 PM GMT+2

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

LANGHORNE, Pa., May 27, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP.

Business Wire 5 days ago

SVRA
Biogen strikes RNAi deal with City; Aurion withdraws IPO

City will receive $46 million from Biogen under the alliance. Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug.

BioPharma Dive 5 days ago

PRTA

BIIB

SVRA
Savara Announces New Employment Inducement Grant

LANGHORNE, Pa., May 23, 2025--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.

Business Wire 9 days ago

SVRA
Savara Announces Participation in Jefferies Global Healthcare Conference

LANGHORNE, Pa., May 22, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20am ET/6:20am PT.

Business Wire 10 days ago

SVRA
Savara Inc. (SVRA): Analysts See 212% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Savara Inc. (NASDAQ:SVRA) was one of the stocks that was covered in that article. Wall Street analysts believe SVRA has a 212% upside potential over the next 12 months. Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company dedicated to addressing the unmet […]

Insider Monkey 11 days ago

SVRA
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

LANGHORNE, Pa., May 18, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with aPAP.

Business Wire 14 days ago

SVRA
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

LANGHORNE, Pa., May 13, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2025 and provided a business update.

Business Wire 19 days ago

SVRA
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

LANGHORNE, Pa., May 12, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30pm ET/1:30pm PT.

Business Wire 20 days ago

SVRA
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

LANGHORNE, Pa., May 01, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will be hosting 1x1 meetings and participating in a fireside chat at the Citizens Life Sciences Conference on Thursday, May 8, 2025 at 10:30am EST/7:30am PST.

Business Wire last month

SVRA
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

LANGHORNE, Pa., April 07, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at the 65th Annual Meeting of the Japanese Respiratory Society (JRS) taking place April 11-13,

Business Wire last month

SVRA
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

LANGHORNE, Pa., March 27, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2024 and provided a business update.

Business Wire 2 months ago

SVRA
Savara Gets Up to $200 Million Loan From Hercules Capital

Savara (SVRA) said Wednesday it entered into a loan and security agreement of up to $200 million wit

PREMIUM
MT Newswires 2 months ago

SVRA

HTGC
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

LANGHORNE, Pa., March 26, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara’s balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a treat

Business Wire 2 months ago

SVRA
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa., March 26, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP.

Business Wire 2 months ago

SVRA
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

LANGHORNE, Pa., March 17, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled "Advances in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)" at the meeting.

Business Wire 2 months ago

SVRA
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

LANGHORNE, Pa., March 06, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an evolution of the first serum-based assay the Company launched. The DBS test helps obtain a diagnosis of aPAP, a rare autoimmune lung disease caused by antibodies targeting GM-CSF, with only a finger-prick blood sample.

Business Wire 2 months ago

SVRA
Savara Announces Participation in the Leerink Global Healthcare Conference

LANGHORNE, Pa., March 03, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT.

Business Wire 2 months ago

SVRA
Positive Signs As Multiple Insiders Buy Savara Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. 3 months ago

SVRA
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

LANGHORNE, Pa., January 30, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, "Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis Treated with Molgramostim Inhalation Solution" was published online in the journal ERJ Open Research. The outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, r

Business Wire 3 months ago

SVRA
Savara Announces Participation in Upcoming Healthcare Investor Conferences

LANGHORNE, Pa., January 29, 2025--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each.

Business Wire 3 months ago

SVRA

Performance Overview

Return	YB4P.DU	S&P 500 (^GSPC)
YTD	-31.97%	+0.51%
1-Year	-47.09%	+12.92%
3-Year	+65.08%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Savara Inc (YB4P.DU)

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

Biogen strikes RNAi deal with City; Aurion withdraws IPO

Savara Announces New Employment Inducement Grant

Savara Announces Participation in Jefferies Global Healthcare Conference

Savara Inc. (SVRA): Analysts See 212% Upside Potential

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025

Savara Reports First Quarter 2025 Financial Results and Provides a Business Update

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences

Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Savara Gets Up to $200 Million Loan From Hercules Capital

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces Participation in the Leerink Global Healthcare Conference

Positive Signs As Multiple Insiders Buy Savara Stock

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara Announces Participation in Upcoming Healthcare Investor Conferences

Performance Overview